Cancer Immunology, Immunotherapy

, Volume 53, Issue 3, pp 262–274 | Cite as

Tumour escape: antitumour effectors too much of a good thing?

Review

Abstract

Although even “spontaneous” tumours are immunogenic and are commonly infiltrated by tumour antigen-specific T cells (at least in melanoma), most tumours are not completely rejected by the host, and cancer progresses. There is a growing realisation that many responses defined as antitumour effector mechanisms act as double-edged swords and under different conditions either become ineffective or even protumorigenic. Examples are interleukin 2 (also proapoptotic for activated T cells), interferon γ (by induction of ligands for T and NK cell inhibitory receptors), angiogenesis inhibition (by hypoxia-mediated induction of growth factors promoting metastasis), and macrophage free radical-mediated cytotoxicity (by inhibiting T cells). Immune selection pressure itself, resulting in outgrowth of resistant tumour variants could also be viewed in this light. On the other hand, knowledge of the many tumour escape pathways offers the theoretical possibility of reconstituting antitumour immunity. Tumour escape from immunosurveillance represents the last series of hurdles to be overcome in formulating truly effective cancer immunotherapy, but given the immense plasticity of the tumour cell, and the complex balance between pro- and antitumour activity of the very same effector pathways, this remains a major challenge.

Keywords

Tumour antigen Immunosurveillance Tumour rejection T cell–mediated immunity Escape 

Notes

Acknowledgements

Experimental work in the author’s laboratory was supported by the Deutsche Forschungsgemeinschaft (Pa 361/5-3, Pa 361/7-1), the Deutsche Krebshilfe (10-1173-Pa3, 10-1698-Pa5), and the Dieter Schlag Foundation; collaborations were supported by EU projects “ESTDAB” (QLRI-CT-2001-01325), “OISTER” (QLGI-CT-2002-00668), ImAginE (QLK6-CT-1999-02031) and T-CIA (QLK6-CT-2002-02283).

References

  1. 1.
    Aarli A, Kristoffersen EK, Jensen TS, Ulvestad E, Matre R (1997) Suppressive effect on lymphoproliferation in vitro by soluble annexin II released from isolated placental membranes. Am J Reprod Immunol 38:313PubMedGoogle Scholar
  2. 2.
    Alleva DG, Burger CJ, Elgert KD (1993) Interferon-gamma reduces tumour-induced macrophage-mediated suppression: role of prostaglandin-E2 and tumour necrosis factor-alpha. Immunopharmacology 25:215CrossRefPubMedGoogle Scholar
  3. 3.
    Alleva DG, Walker TM, Elgert KD (1995) Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages. J Leukocyte Biol 57:919PubMedGoogle Scholar
  4. 4.
    Amiot L, Onno M, Lamy T, Dauriac C, Le Prise PY, Fauchet R, Drenou B (1998) Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 100:655CrossRefPubMedGoogle Scholar
  5. 5.
    Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881PubMedGoogle Scholar
  6. 6.
    Ardouin L, Boyer C, Gillet A, Trucy J, Bernard AM, Nunes J, Delon J, Trautmann A, He HT, Malissen B, Malissen M (1999) Crippling of CD3-zeta ITAMs does not impair T cell receptor signaling. Immunity 10:409PubMedGoogle Scholar
  7. 7.
    Atassi T, Thuluvath PJ (2003) Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol 37:72CrossRefPubMedGoogle Scholar
  8. 8.
    Bai XF, Liu J, Li O, Zheng P, Liu Y (2003) Antigenic drift as a mechanism for tumour evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111:1487CrossRefPubMedGoogle Scholar
  9. 9.
    Barzegar C, Meazza R, Pereno R, Pottin-Clemenceau C, Scudeletti M, Brouty-Boye D, Doucet C, Taoufik Y, Ritz J, Musselli C, Mishal Z, Jasmin C, Indiveri F, Ferrini S, Azzarone B (1998) IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene 16:2503CrossRefPubMedGoogle Scholar
  10. 10.
    Beatty GL, Paterson Y (2000) IFN-gamma can promote tumour evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumour antigen. J Immunol 165:5502PubMedGoogle Scholar
  11. 11.
    Bennett MW, O’Connell J, O’Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F (1998) The Fas counterattack in vivo: apoptotic depletion of tumour-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669PubMedGoogle Scholar
  12. 12.
    Bergmann-Leitner ES, Abrams SI (2000) Influence of interferon gamma on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack. Cancer Immunol Immunother 49:193PubMedGoogle Scholar
  13. 13.
    Bergmann-Leitner ES, Abrams SI (2001) Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4+ T cell response in human carcinoma immune interactions. Cell Immunol 209:49CrossRefPubMedGoogle Scholar
  14. 14.
    Buggins AG, Hirst WJ, Pagliuca A, Mufti GJ (1998) Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol 100:784CrossRefPubMedGoogle Scholar
  15. 15.
    Byrne SN, Halliday GM (2003) High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress. Cancer Immunol Immunother 52:396PubMedGoogle Scholar
  16. 16.
    Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumour tissues. Cancer Immunol Immunother 52:1PubMedGoogle Scholar
  17. 17.
    Capelli E, Civallero M, Barni S, Ceroni M, Nano R (1999) Interleukin-2 induces the growth of human glioblastoma cells in culture. Anticancer Res 19:3147PubMedGoogle Scholar
  18. 18.
    Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, Manzo C, Karre K, Zappacosta S (1999) Recognition of autologous dendritic cells by human NK cells. Eur J Immunol 29:4022CrossRefPubMedGoogle Scholar
  19. 19.
    Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L (2003) Suboptimal activation of CD8+ T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res 63:1560PubMedGoogle Scholar
  20. 20.
    Cerwenka A, Lanier LL (2003) NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61:335CrossRefPubMedGoogle Scholar
  21. 21.
    Chappell DB, Restifo NP (1998) T cell-tumour cell: a fatal interaction? Cancer Immunol Immunother 47:65CrossRefPubMedGoogle Scholar
  22. 22.
    Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW (2000) Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231:552CrossRefPubMedGoogle Scholar
  23. 23.
    Chaux P, Moutet M, Faivre J, Martin F, Martin M (1996) Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74:975PubMedGoogle Scholar
  24. 24.
    Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M (2000) Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol 111:817CrossRefPubMedGoogle Scholar
  25. 25.
    Choi SH, Chung EJ, Whang DY, Lee SS, Jang YS, Kim CW (1998) Alteration of signal-transducing molecules in tumour-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer Immunol Immunother 45:299PubMedGoogle Scholar
  26. 26.
    Chouaib S, Thiery J, Gati A, Guerra N, El Behi M, Dorothee G, Mami-Chouaib F, Bellet D, Caignard A (2002) Tumour escape from killing: role of killer inhibitory receptors and acquisition of tumour resistance to cell death. Tissue Antigens 60:273CrossRefPubMedGoogle Scholar
  27. 27.
    Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD (2003) Impact of the tumour microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 52:535Google Scholar
  28. 28.
    Contreras DN, Krammer PH, Potkul RK, Bu P, Rossi JL, Kaufmann AM, Gissmann L, Qiao L (2000) Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother 23:67CrossRefPubMedGoogle Scholar
  29. 29.
    Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M (1992) Interleukin-4 protects chronic lymphocytic leukemic B-cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176:1319PubMedGoogle Scholar
  30. 30.
    Debinski W, Puri RK, Kreitman RJ, Pastan I (1993) A wide range of human cancers express interleukin-4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and pseudomonas exotoxin. J Biol Chem 268:14065PubMedGoogle Scholar
  31. 31.
    de Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:365CrossRefPubMedGoogle Scholar
  32. 32.
    de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes—an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209PubMedGoogle Scholar
  33. 33.
    Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE (1999) CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumour vaccine efficacy. Nature Med 5:774PubMedGoogle Scholar
  34. 34.
    Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumour-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793PubMedGoogle Scholar
  35. 35.
    Dowlati A, Levitan N and Remick SC (1999) Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med 134:405PubMedGoogle Scholar
  36. 36.
    Dudley ME, Roopenian DC (1996) Loss of a unique tumour antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 184:441PubMedGoogle Scholar
  37. 37.
    Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V (2000) A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumour-specific immune response. J Immunol 165:6644PubMedGoogle Scholar
  38. 38.
    Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 3:991CrossRefPubMedGoogle Scholar
  39. 39.
    Effros R, Pawelec G (1997) Replicative senescence of T lymphocytes: does the Hayflick Limit lead to immune exhaustion? Immunol Today 18:450CrossRefPubMedGoogle Scholar
  40. 40.
    Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F, Bonnotte B (2000) Flt3 ligand lessens the growth of tumours obtained after colon cancer cell injection in rats but does not restore tumour-suppressed dendritic cell function. Int J Cancer 86:827CrossRefPubMedGoogle Scholar
  41. 41.
    Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S, Kurzrock R (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97:256CrossRefPubMedGoogle Scholar
  42. 42.
    Frassanito MA, Cusmai A, Iodice G, Dammacco F (2001) Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97:483CrossRefPubMedGoogle Scholar
  43. 43.
    Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55:4140PubMedGoogle Scholar
  44. 44.
    Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Ito T, Sugimoto C, Saito H (2000) Expression of Fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma. Cancer Lett 161:73CrossRefPubMedGoogle Scholar
  45. 45.
    Fujihara T, Yashiro M, Inoue T, Sawada T, Kato Y, Ohira M, Nishiguchi Y, Ishikawa T, Sowa M, Chung KH (1999) Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymph node metastasis. Gastric Cancer 2(4):221–225CrossRefPubMedGoogle Scholar
  46. 46.
    Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumour variants. Int J Cancer 91:109PubMedGoogle Scholar
  47. 47.
    Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumour immune escape. J Cell Physiol 195:346CrossRefPubMedGoogle Scholar
  48. 48.
    Gastman BR, Johnson DE, Whiteside TL, Rabinowich H (1999) Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 59:1422PubMedGoogle Scholar
  49. 49.
    Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD (1995) Malignant disease in patients with long-term renal transplants. Transplantation 59:1705PubMedGoogle Scholar
  50. 50.
    Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumour reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112PubMedGoogle Scholar
  51. 51.
    Gratama JW, Zea AH, Bolhuis RL, Ochoa AC (1999) Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol Immunother 48:263PubMedGoogle Scholar
  52. 52.
    Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H (1998) Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58:2057PubMedGoogle Scholar
  53. 53.
    Grothey A, Heistermann P, Philippou S, Voigtmann R (1998) Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer 77:801PubMedGoogle Scholar
  54. 54.
    Guerra N, Benlhassan K, Carayol G, Guillard M, Pardoux C, Chouaib S, Caignard A (1999) Effect of tumour growth factor-beta on NK receptor expression by allostimulated CD8(+) T lymphocytes. Eur Cytokine Netw 10:357PubMedGoogle Scholar
  55. 55.
    Guindi M (2000) Role of activated host T cells in the promotion of MALT lymphoma growth. Semin Cancer Biol 10:341CrossRefPubMedGoogle Scholar
  56. 56.
    Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cheroutre H, Fowell DJ, Binder S, Tsao B, Locksley RM, Moore KW, Kronenberg M (1997) Altered immune responses in interleukin 10 transgenic mice. J Exp Med 185:2101CrossRefGoogle Scholar
  57. 57.
    Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumour immune escape. Science 274:1363PubMedGoogle Scholar
  58. 58.
    Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L (1999) On down-regulation of the immune response to metastatic malignant melanoma. Cancer Immunol Immunother 48:253PubMedGoogle Scholar
  59. 59.
    Halder TM, Bluggel M, Heinzel S, Pawelec G, Meyer HE, Kalbacher H (2000) Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumour patients (Plasmacytoma, chronic myeloid leukemia). Blood 95:2890PubMedGoogle Scholar
  60. 60.
    Hammond WG, Benfield JR, Tesluk H, Johnson J R, Teplitz R L (1995) Tumour progression by lung cancers growing in hosts of different immunocompetence. Cancer J 8:130Google Scholar
  61. 61.
    Han D, Pottin-Clemenceau C, Imro MA, Scudeletti M, Doucet C, Puppo F, Brouty-Boye D, Vedrenne J, Sahraoui Y, Brailly H, Poggi A, Jasmin C, Azzarone B, Indiveri F (1996) IL2 triggers a tumour progression process in a melanoma cell line MELP, derived from a patient whose metastasis increased in size during IL2/IFNa biotherapy. Oncogene 12:1015PubMedGoogle Scholar
  62. 62.
    Holub M, Zakeri SM, Lichtenberger C, Pammer J, Paolini P, Leifeld L, Rockenschaub S, Wolschek MF, Steger G, Willheim M, Gangl A, Reinisch W (2003) Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 15:119CrossRefPubMedGoogle Scholar
  63. 63.
    Huang M, Sharma S, Mao JT, Dubinett SM (1996) Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL 10 transcription and protein production. J Immunol 157:5512PubMedGoogle Scholar
  64. 64.
    Huang SY, Ullrich SE, BarEli M (1999) Regulation of tumour growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19:697CrossRefPubMedGoogle Scholar
  65. 65.
    Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH (1999) A proinflammatory cytokine inhibits p53 tumour suppressor activity. J Exp Med 190:1375PubMedGoogle Scholar
  66. 66.
    Hünig T (1983) T cell function and specificity in athymic mice. Immunol Today 4:84Google Scholar
  67. 67.
    Jager MJ, Hurks HM, Levitskaya J, Kiessling R (2002) HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol 63:444CrossRefGoogle Scholar
  68. 68.
    Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T (1998) Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112:166CrossRefPubMedGoogle Scholar
  69. 69.
    Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma—association with disease progression. Am J Pathol 154:745Google Scholar
  70. 70.
    Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA (2002) Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169:1984PubMedGoogle Scholar
  71. 71.
    Kharkevitch DD, Seito D, Balch GC, Maeda T, Balch CM, Itoh K (1994) Characterization of autologous tumour-specific T-helper 2 cells in tumour-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer 58:317PubMedGoogle Scholar
  72. 72.
    Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000) Tumours promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164:1269PubMedGoogle Scholar
  73. 73.
    Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K (1995) IL-10 production in cutaneous basal and squamous cell carcinomas—a mechanism for evading the local T cell immune response. J Immunol 155:2240PubMedGoogle Scholar
  74. 74.
    Kim JA, Dayton MA, Aldrich W, Triozzi PL (1999) Modulation of CD4 cell cytokine production by colon cancer-associated mucin. Cancer Immunol Immunother 48:525CrossRefPubMedGoogle Scholar
  75. 75.
    Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R (1996) Hydrogen peroxide secreted by tumour-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumour-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308PubMedGoogle Scholar
  76. 76.
    Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961PubMedGoogle Scholar
  77. 77.
    Koulis A, Diss T, Isaacson PG, Dogan A (1997) Characterization of tumour-infiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 151:1353Google Scholar
  78. 78.
    Koyama S, Maruyama T, Adachi S, Nozue M (1998) Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Cancer Res Clin Oncol 124:383CrossRefPubMedGoogle Scholar
  79. 79.
    Kuhn DJ, Smith DM, Pross S, Whiteside TL, Dou QP (2003) Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.J Cell Biochem 89:824CrossRefPubMedGoogle Scholar
  80. 80.
    Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B (1998) Clonal deletion of thymocytes as a tumour escape mechanism. Int J Cancer 78:216CrossRefPubMedGoogle Scholar
  81. 81.
    Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumour-associated antigens in melanoma patients. Nat Med 5:677PubMedGoogle Scholar
  82. 82.
    Lindelof B, Sigurgeirsson B, Gabel H, Stern RS (2000) Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143:513CrossRefPubMedGoogle Scholar
  83. 83.
    Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E (2003) Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Clin Cancer Res 9:722PubMedGoogle Scholar
  84. 84.
    Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP, Wilder RL, Elenkov IJ (2000) Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 164:436PubMedGoogle Scholar
  85. 85.
    Liu L, Rich BE, Inobe J, Chen W, Weiner HL (1998) Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol 10:1017CrossRefPubMedGoogle Scholar
  86. 86.
    Loftus DJ, Squarcina P, Nielsen MB, Geisler C, Castelli C, Odum N, Appella E, Parmiani G, Rivoltini L (1998) Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res 58:2433PubMedGoogle Scholar
  87. 87.
    Maclean GD, Reddish MA, Longenecker BM (1997) Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother 20:70PubMedGoogle Scholar
  88. 88.
    Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, Lenkei R, Masucci G, Pettersson S, Kiessling R (2001) Inhibition of activated/memory (CD45RO+) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 167:2595PubMedGoogle Scholar
  89. 89.
    Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J, Kiessling R (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.J Clin Invest 110:1515CrossRefPubMedGoogle Scholar
  90. 90.
    Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumour-associated macrophages. Immunol Today 13:265PubMedGoogle Scholar
  91. 91.
    Matsui K, O’Mara LA, Allen PM (2003) Successful elimination of large established tumours and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol 15:797CrossRefPubMedGoogle Scholar
  92. 92.
    McMillan DN, Kernohan NM, Flett ME, Heys SD, Deehan DJ, Sewell HF, Walker F, Eremin O (1995) Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumour cells in situ and in vitro: Evidence for a direct role in the regulation of tumour cell proliferation. Int J Cancer 60:766PubMedGoogle Scholar
  93. 93.
    Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20:469CrossRefPubMedGoogle Scholar
  94. 94.
    Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ (2002) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest. 82:1725Google Scholar
  95. 95.
    Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in lymphocytes-T from tumour-bearing mice. Science 258:1795PubMedGoogle Scholar
  96. 96.
    Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM (2003) The dual role of IL-10. Trends Immunol 24:36CrossRefPubMedGoogle Scholar
  97. 97.
    Morse MA, Clay TM, Mosca P, Lyerly HK (2002) Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2:827PubMedGoogle Scholar
  98. 98.
    Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C (1999) Is there any relationship between interleukin-6/ interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 9:181PubMedGoogle Scholar
  99. 99.
    Muschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW (2000) CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 99:69PubMedGoogle Scholar
  100. 100.
    Nagashima H, Mori M, Sadanaga N, Mashino K, Yoshikawa Y, Sugimachi K (2001) Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 18:1157PubMedGoogle Scholar
  101. 101.
    Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, Tomura M, Ono S, Tsujimura T, Fujiwara H, Hamaoka T (2001) A role of interferon-gamma (IFN-gamma) in tumour immunity: T cells with the capacity to reject tumour cells are generated but fail to migrate to tumour sites in IFN-gamma-deficient mice. Cancer Res 61:3399PubMedGoogle Scholar
  102. 102.
    Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV (1998) Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188:341CrossRefPubMedGoogle Scholar
  103. 103.
    Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, Fisher SG, Velders MP, Petersson M, Kiessling R, Kast WM (1998) PBLs of early breast carcinoma patients with a high nuclear grade tumour unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J Immunother 21:317PubMedGoogle Scholar
  104. 104.
    Nyhus JK, Wolford C, Feng L, Barbera-Guillem E (2001) Direct in vivo transfection of antisense Fas-ligand reduces tumour growth and invasion. Gene Therapy 8:209CrossRefPubMedGoogle Scholar
  105. 105.
    Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumour rejection by in vivo administration of anti-CD25 (Interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128PubMedGoogle Scholar
  106. 106.
    Ouyang Q, Wagner W, Walter S, Wikby A, Aubert G, Müller CA, Klatt T, Stevanovic S, Rammensee HG, Dodi T, Travers P, Pawelec G (2003) The age-related increase in CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counterbalanced by decreased antigen-specific responsiveness. Mech Ageing Dev 124:477CrossRefPubMedGoogle Scholar
  107. 107.
    Ouyang Q, Wagner W, Wikby A, Walter S, Aubert G, Dodi T, Travers P, Pawelec G (2003) Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol 23:247Google Scholar
  108. 108.
    Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759CrossRefPubMedGoogle Scholar
  109. 109.
    Pawelec G (1999) Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48:343PubMedGoogle Scholar
  110. 110.
    Pawelec G, Hambrecht A, Rehbein A, Adibzadeh M (1996) Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death. Cytokine 8:877CrossRefPubMedGoogle Scholar
  111. 111.
    Pawelec G, Schlotz E, Rehbein A (1999) IFN-alpha regulates IL 10 production by CML cells in vitro. Cancer Immunol Immunother 48:430CrossRefPubMedGoogle Scholar
  112. 112.
    Pawelec G, Barnett Y, Mariani E, Solana R (2002) Human CD4+ T cell clone longevity in tissue culture: lack of influence of donor age or cell origin. Exp Gerontol 37:265CrossRefPubMedGoogle Scholar
  113. 113.
    Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J (2003) Gangliosides from human melanoma tumours impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 170:3488PubMedGoogle Scholar
  114. 114.
    Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) T lymphocytes that infiltrate tumours and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A 92:6547PubMedGoogle Scholar
  115. 115.
    Ponzio NM, Thorbecke GJ (2000) Requirement for reverse immune surveillance for the growth of germinal center-derived murine lymphomas. Semin Cancer Biol 10:331CrossRefPubMedGoogle Scholar
  116. 116.
    Poppema S, van den Berg A (2000) Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 10:345CrossRefPubMedGoogle Scholar
  117. 117.
    Powrie F, Menon S, Coffman RL (1993) Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 23:3043PubMedGoogle Scholar
  118. 118.
    Prehn RT (1994) Stimulatory effects of immune reactions upon the growths of untransplanted tumours. Cancer Res 54:908PubMedGoogle Scholar
  119. 119.
    Prehn RT (1995) On the probability of effective anticancer vaccines. Cancer J 8:284Google Scholar
  120. 120.
    Puri RK, Finbloom DS, Leland P, Mostowski H, Siegel JP (1990) Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2. Immunology 70:492PubMedGoogle Scholar
  121. 121.
    Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells—Implications for altered expression of T cell receptor in tumour-associated lymphocytes. J Clin Invest 101:2579PubMedGoogle Scholar
  122. 122.
    Radoja S, Rao TD, Hillman D, Frey AB (2000) Mice bearing late-stage tumours have normal functional systemic T cell responses in vitro and in vivo. J Immunol 164:2619PubMedGoogle Scholar
  123. 123.
    Reichmann E (2002) The biological role of the Fas/FasL system during tumour formation and progression. Semin Cancer Biol 12:309CrossRefPubMedGoogle Scholar
  124. 124.
    Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumour escape. Nat Med 6:493CrossRefPubMedGoogle Scholar
  125. 125.
    Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T, Blankenstein T (1993) Interleukin-10 transfected into Chinese hamster ovary cells prevents tumour growth and macrophage infiltration. Cancer Res 53:4134PubMedGoogle Scholar
  126. 126.
    Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112CrossRefPubMedGoogle Scholar
  127. 127.
    Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP (1999) IL-4-transduced tumour cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol 163:1923PubMedGoogle Scholar
  128. 128.
    Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumour immunity, and transplantation tolerance. Immunol Rev. 182:18Google Scholar
  129. 129.
    Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, Blankenstein T, Ljunggren HG, Kiessling R (1997) Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumour cell lines expressing IL-10. J Immunol 159:3195PubMedGoogle Scholar
  130. 130.
    Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.Int J Cancer 103:642CrossRefPubMedGoogle Scholar
  131. 131.
    Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS (1994) Abnormal signal transduction by T cells of mice with parental tumours is not seen in mice bearing IL-2-secreting tumours. J Immunol 153:5176PubMedGoogle Scholar
  132. 132.
    Sanchez-Rovira P, Jimenez E, Carracedo J, Barneto IC, Ramirez R, Aranda E (1998) Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: Inhibitory effect on cytotoxicity. Eur J Cancer 34:394CrossRefPubMedGoogle Scholar
  133. 133.
    Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F (1999) Interleukin-10 levels are often elevated in serum of adults with Hodgkin’s disease and are associated with inferior failure-free survival. Ann Oncol 10:433CrossRefPubMedGoogle Scholar
  134. 134.
    Schreiber H, Wu TH, Nachman J, Rowley DA (2000) Immunological enhancement of primary tumour development and its prevention. Semin Cancer Biol 10:351CrossRefPubMedGoogle Scholar
  135. 135.
    Seliger B, Maeurer MJ, Ferrone S (1997) TAP off—tumours on. Immunol Today 18:292PubMedGoogle Scholar
  136. 136.
    Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Storkel S (2003) Characterization of human lymphocyte antigen class i antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 9:1721PubMedGoogle Scholar
  137. 137.
    She J, Ruzek MC, Velupillai P, de Aos I, Wang B, Harn DA, Sancho J, Biron CA, Terhorst C (1999) Generation of antigen-specific cytotoxic T lymphocytes and regulation of cytokine production takes place in the absence of CD3 zeta. Int Immunol 11:845CrossRefPubMedGoogle Scholar
  138. 138.
    Shen W, Ladisch S (2002) Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell Immunol 220:125CrossRefPubMedGoogle Scholar
  139. 139.
    Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumour immunity by removing CD25+ CD4+ T cells: a common basis between tumour immunity and autoimmunity. J Immunol 163:5211PubMedGoogle Scholar
  140. 140.
    Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H (2000) Enhanced growth of primary tumours in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 191:1945PubMedGoogle Scholar
  141. 141.
    Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumour progression. Proc Natl Acad Sci U S A 95:1178–1183PubMedGoogle Scholar
  142. 142.
    Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumour cells. Blood 93:1634PubMedGoogle Scholar
  143. 143.
    Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH (2002) CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99:2468CrossRefPubMedGoogle Scholar
  144. 144.
    Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G (1995) Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346:796PubMedGoogle Scholar
  145. 145.
    Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM (2000) Specific inhibition of cyclooxygenase 2 restores antitumour reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361PubMedGoogle Scholar
  146. 146.
    Stutman O (1970) Tumour development after 3-methylcholanthrene in immunologically-deficient nude mice. Science 183:534Google Scholar
  147. 147.
    Taga K, Cherney B, Tosato G (1993) IL-10 inhibits apoptotic cell death in human T-cells starved of IL-2. Int Immunol 5:1599PubMedGoogle Scholar
  148. 148.
    Terheyden P, Siedel C, Merkel A, Kampgen E, Brocker EB, Becker JC (1999) Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. J Invest Dermatol 112:899PubMedGoogle Scholar
  149. 149.
    Thomas WD, Smith MJ, Si Z, Hersey P (1996) Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer 68:795CrossRefPubMedGoogle Scholar
  150. 150.
    Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM (1996) Peptide vaccination can lead to enhanced tumour growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 93:7855PubMedGoogle Scholar
  151. 151.
    Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M (2000) Macrophage infiltration correlates with tumour stage and angiogenesis in human malignant melanoma: possible involvement of TNF alpha and IL-1 alpha. Int J Cancer 85:182PubMedGoogle Scholar
  152. 152.
    Trapani JA (2002) Tumour-mediated apoptosis of cancer-specific T lymphocytes--reversing the “kiss of death”? Cancer Cell 2:169CrossRefPubMedGoogle Scholar
  153. 153.
    Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T (2000) Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 89:2560CrossRefPubMedGoogle Scholar
  154. 154.
    Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumour progression and survival. J Clin Oncol 19:577PubMedGoogle Scholar
  155. 155.
    Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, David Mayer A, Buckels JA, McMaster P, Neuberger J, Mirza DF (2003) Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75:1983CrossRefPubMedGoogle Scholar
  156. 156.
    Viac J, Schmitt D, Claudy A (1997) CD40 expression in epidermal tumours. Anticancer Res 17:569PubMedGoogle Scholar
  157. 157.
    von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC (1999) Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59:1287PubMedGoogle Scholar
  158. 158.
    Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK (1997) An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76:836PubMedGoogle Scholar
  159. 159.
    Wajant H, Pfizenmaier K, Scheurich P (2003) Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 14:53CrossRefPubMedGoogle Scholar
  160. 160.
    Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670CrossRefPubMedGoogle Scholar
  161. 161.
    Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WC, Johnson JT, Herberman RB, Azzarone B, Whiteside TL (1992) Receptors for interleukin-2 on human squamous cell carcinoma cell lines and tumour in situ. Cancer Res 52:5963PubMedGoogle Scholar
  162. 162.
    Whiteside TL (1999) Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48:346PubMedGoogle Scholar
  163. 163.
    Whiteside TL (2002) Tumour-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 12:43CrossRefPubMedGoogle Scholar
  164. 164.
    Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumours. J Clin Invest 109:651CrossRefPubMedGoogle Scholar
  165. 165.
    Willers J, Urosevic M, Laine E, Geertsen R, Kundig T, Burg G, Dummer R (2001) The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumour cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation. J Invest Dermatol 116:874CrossRefPubMedGoogle Scholar
  166. 166.
    Yang G, Hellstrom KE, Mizuno MT, Chen L (1995) In vitro priming of tumour-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 155:3897PubMedGoogle Scholar
  167. 167.
    Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, Fujita S (1998) CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 92:3355PubMedGoogle Scholar
  168. 168.
    Yasumura S, Lin WC, Weidmann E, Hebda P, Whiteside TL (1994) Expression of interleukin 2 receptors on human carcinoma cell lines and tumour growth inhibition by interleukin 2. Int J Cancer 59:225PubMedGoogle Scholar
  169. 169.
    Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G (1997) Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-1, HLA class-II and ICAM-1 molecules. Int J Cancer 71:630CrossRefPubMedGoogle Scholar
  170. 170.
    Zavos G, Bokos J, Papaconstantinou J, Boletis J, Gazouli M, Pappas P, Kostakis A (2003) Study of “de novo” malignancies among Greek renal transplant recipients. Transplant Proc 35:1399CrossRefPubMedGoogle Scholar
  171. 171.
    Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, Hammerschmidt W (1997) Downregulation of TAP-1 in B lymphocytes by cellular and Epstein-Barr virus-encoded Interleukin 10. Blood 90:2390PubMedGoogle Scholar
  172. 172.
    Zhang GJ, Adachi I (1999) Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. AntiCancer Res 19:1427PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Center for Medical Research (ZMF)University of TübingenTübingenGermany

Personalised recommendations